Innovations in Immunity
Learn more about Eurofins Viracor inSIGHT™ for examining T cell response:
It's your job to keep patients safe; our job is to help you do it.
With inSIGHT™, you're now armed with the data to help answer critical questions: Is the patient's body producing a T Cell response? Is that response strong enough to make treatment adjustments? Are they ready to discontinue antiviral medication?
For Clinical Staff
For Lab Staff
|Dr. Nirav Raval
Medical Director of Thoracic Transplant, Transplant Cardiologist
|Dr. Fareed Khawaja
Assistant Professor, Department of Infectious diseases, Infection Control and Employee Health
University of Texas MD Anderson Cancer Center
|Dr. Steve Kleiboeker
Vice President of Research and Development
Eurofins US Clinical Diagnostics
Join Dr.'s Raval, Khawaja and Kleiboeker to learn more about virus-specific T cell immunity for CMV and SARS-CoV-2. Dr. Raval, a board-certified Cardiologist, will share his experience utilizing the CMV T Cell Immunity panel in heart transplant patients. Dr. Khawaja, an Infectious Disease physician, will present his experience with CMV cellular immunity in hematopoietic cell transplant recipients with low level viremia. Finally, Dr. Kleiboeker will describe the new SARS-CoV-2 inSIGHT T Cell Immunity test as well as discuss future T Cell Immunity testing innovations to come.
T Cell Immunity Testing - Flow Cytometry
inSIGHT™ utilizes intracellular cytokine staining analyzed by flow cytometry to measure the strength of T cell responses to viral specific antigens or proteins. It evaluates and reports the activity of CD4 and CD8 T Cell responses separately.
… Unlike ELISpot or QuantiFERONassays, ICS can thus provide both quantitative and qualitative characteristics of CMV-specific T cells.”
Explore by Category